Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

Stopped early · Phase 2

Conditions studied: Small Cell Lung Cancer

In brief

The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.

Key facts

Study ID

NCT00316433

Run by

Swedish Medical Center

People needed

24

Starts

2005-02-01

Expected to finish

2007-01-01

Last updated by the study team

2007-04-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previously untreated extensive small cell lung cancer
• No prior chemotherapy
• No prior radiotherapy except for the treatment of brain metastases

You may not qualify if…

• Prior treatment for extensive stage small cell lung cancer
• Known hypersensitivity to any of the components of oxaliplatin or CPT-11
• Greater than grade 2 peripheral neuropathy
• Known HIV or Hepatitis B or C (active, previously treated or both)

Where it is running

• Swedish Medical Center Cancer Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.